TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Invion ( (AU:IVX) ) has provided an update.
Invion Limited has entered into a collaboration with Protect Animal Health Inc. to explore the use of Photosoft™ technology for treating cancer in companion animals. This partnership aims to tap into the growing pet cancer therapeutics market, which is projected to reach $12.1 billion by 2034. Protect will conduct studies funded by them, potentially leading to a co-development agreement for commercialization if successful. This collaboration aligns with Invion’s strategy to expand the application of Photosoft beyond human health, potentially accelerating commercialization in the companion animal sector.
More about Invion
Invion is a life-science company focused on the global research and development of Photosoft™ technology for treating various cancers, atherosclerosis, and infectious diseases. The company holds exclusive licensing rights in specific regions for these treatments and is listed on the ASX. Research and clinical trials are funded by RMW Cho Group Limited.
Average Trading Volume: 129,682
Technical Sentiment Signal: Sell
Current Market Cap: A$8.39M
Learn more about IVX stock on TipRanks’ Stock Analysis page.